Mono Pharmacare Ltd (MONOPHARMA) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Mono Pharmacare Ltd on NSE and BSE, with an AI summary of each filing.
Mono Pharmacare Limited has informed regarding Submission of the Compliance Report on Corporate Governance for the Q2 FY 2026-27
Others (Uncategorized) · 27 Oct 2026, 11:34 pm
Mono Pharmacare Cites SME Listing Exemption for Corporate Governance Filing Mono Pharmacare Limited confirmed to the National Stock Exchange of India that submission of the Corporate Governance Report under Regulation 27(2) is not applicable for the quarter ended 30th Sep'26. The company invoked exemptions under Regulation 15(2)(b) of Chapter IV of SEBI (LODR) Regulations, 2015, which exempts companies listed on the SME exchange from this filing requirement.
Integrated filing governance for quarter 2 2026-27
Others (Uncategorized) · 27 Oct 2026, 11:29 pm
Mono Pharmacare Regulatory Filings for Q2 FY27 Mono Pharmacare confirmed the non-applicability of submitting a Corporate Governance Report under Regulation 27(2) for the quarter ended 30th Sep'26, citing SEBI (LODR) Regulation 15(2)(b) exemptions applicable to SME exchange-listed companies. Separately, the investor grievance report issued by registrar Bigshare Services Pvt. Ltd. confirmed zero investor complaints pending, received, or resolved during the period from 1st Jul'26 to 30th Sep'26.
Integrated filing governance for quarter 1 2026-27
Others (Uncategorized) · 15 Oct 2026, 8:58 pm
Mono Pharmacare Reports Compliance Exemptions and Investor Grievance Status Mono Pharmacare confirmed that submission of the Corporate Governance Report under Regulation 27(2) is not applicable for the quarter ended 30th Jun'26, citing SEBI LODR Regulation 15(2)(b) exemptions for SME-listed companies. Separately, the investor grievance report issued by registrar Bigshare Services Pvt. Ltd. for the period 31st Mar'26 to 30th Jun'26 recorded zero pending complaints at the start of the quarter, zero complaints received, zero resolved, and zero complaints outstanding at the end of the period.
Mono Pharmacare Limited has informed regarding Submission of the Compliance Report on Corporate Governance for the Q1 FY 2026-27
Others (Uncategorized) · 15 Oct 2026, 8:53 pm
Mono Pharmacare Exempt from Corporate Governance Report for Q1 FY27 Mono Pharmacare Limited announced that it is exempt from submitting the Corporate Governance Report under Regulation 27(2) of SEBI (LODR) Regulations, 2015, for the quarter ended 30th Jun'26. The exemption applies pursuant to Regulation 15(2)(b) of Chapter IV, as the company’s equity shares are listed on the SME exchange platform.
Mono Pharmacare Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 30, 2026. Further, the company has informed the Exchange regarding voting results.
Annual General Meeting · 02 Oct 2026, 10:28 pm
Mono Pharmacare Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 30, 2026
Annual General Meeting · 30 Sept 2026, 10:32 pm
Mono Pharmacare Limited has informed the Exchange that Record date for the purpose of Meeting is 23-Sep-2026.
Others · 18 Sept 2026, 12:08 am
Mono Pharmacare Fixes Record Date for AGM Remote E-Voting Mono Pharmacare Limited has fixed Wednesday, 23rd Sep'26 as the record date to determine shareholder eligibility for remote e-voting at its Annual General Meeting for FY25-26. The company's Annual General Meeting is scheduled to be conducted on 30th Sep'26.
Mono Pharmacare Limited has informed the Exchange regarding 'Board comment on fine levied'.
Others (Uncategorized) · 09 Sept 2026, 11:13 pm
Mono Pharmacare Fined by NSE for Regulatory Non-Compliance NSE levied penalties totaling ₹2,02,960 on Mono Pharmacare Limited for compliance delays, including ₹1,71,100 under Regulation 33 of SEBI LODR Regulations, 2015, and ₹31,860 under Regulation 76 of SEBI (Depositories and Participants) Regulations, 2018, following notices issued on 30th Jun'26 and 5th Jun'26, respectively. The company confirmed it has taken corrective actions to achieve full compliance, while the Board directed management to strengthen internal compliance mechanisms to avoid future regulatory lapses.
Mono Pharmacare Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 30, 2026
Annual General Meeting · 04 Sept 2026, 9:51 pm
Mono Pharmacare Limited has informed the Exchange regarding Outcome of Board Meeting held on September 03, 2026.
Outcome · 04 Sept 2026, 12:07 am
Mono Pharmacare Board Approves AGM Dates, Auditor Appointment, and Acknowledges Non-Compliance On 3rd Sep'26, Mono Pharmacare's board scheduled its 4th AGM for 30th Sep'26, establishing 23rd Sep'26 as the record date. Key resolutions include the reappointment of Mr. Panilam Lakhatariya as director and the appointment of R K MERGU & CO as statutory auditors for a five-year term. The board approved the FY26 Directors Report and reviewed the Secretarial Auditor's Report for FY26. Notably, directors officially acknowledged NSE reminders regarding non-compliance with Regulation 76 of the SEBI (Depositories and Participants) Regulations, 2018.
Mono Pharmacare Limited has informed the Exchange about Board Meeting to be held on 03-Sep-2026 to consider Other business.
Intimation · 27 Aug 2026, 12:23 am
Mono Pharmacare Board to Meet on Sep 3rd for Other Business Mono Pharmacare Limited has scheduled a Board Meeting for 03-Sep-26. The agenda for the meeting is to consider and discuss unspecified "Other business" items.
To consider other business matters
Others (Uncategorized) · 27 Aug 2026, 12:13 am
Mono Pharmacare Board Meeting to Approve FY26 Report, Appoint Auditor Mono Pharmacare has scheduled a board meeting on 03 Sep'26. Key agenda items include approving the Directors' Report for the financial year ended 31 Mar'26, and considering the appointment of M/s R K MERGU & CO as statutory auditors for a five-year term. The board will also decide the date and record date for the upcoming Annual General Meeting (AGM). Additional matters include the re-appointment of Mr. Panilam Lakhatariya as a director and reviewing the Secretarial Auditor's Report for FY 2025-26.
Mono Pharmacare Limited has informed the Exchange about General Updates regarding the re-appointment of Secretarial Auditor of the company.
Others (Uncategorized) · 17 Jul 2026, 12:34 am
Mono Pharmacare Re-Appoints Secretarial Auditor for FY27 Mono Pharmacare's Board of Directors approved the re-appointment of M/s Surana and Kothari Associates LLP as the Secretarial Auditor for the financial year 2026-27. The decision was made during the board meeting held on 16 Jul'26, based on the recommendation of the Audit Committee. This appointment is effective from 16 Jul'26 and is intended to comply with the Companies Act, 2013 and SEBI Listing Regulations.
Mono Pharmacare Limited has informed the Exchange regarding Change in Auditors of the company.
Change in Auditor · 17 Jul 2026, 12:06 am
Mono Pharmacare Appoints B G Kalal & Co as Internal Auditor for FY27 Mono Pharmacare's Board of Directors has approved the appointment of M/s B G Kalal & Co, Chartered Accountants, as the company's Internal Auditor for the financial year 2026-27. The appointment, based on the Audit Committee's recommendation, is effective from 16 Jul'26. This move is to comply with the Companies Act, 2013 and SEBI Listing Regulations. B G Kalal & Co has experience in internal audit and internal financial controls reviews. No relationships were disclosed between the appointee and the company's directors.
Mono Pharmacare Limited has informed the Exchange about Resignation of Director/KMP/SMP
Change in Management · 17 Jul 2026, 12:03 am
Mono Pharmacare Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
Outcome · 16 Jul 2026, 11:42 pm
Mono Pharmacare FY26 Results: PAT Declines Sharply on Lower Revenue and Margins Mono Pharmacare reported consolidated FY26 revenue of ₹16,570.59 lakhs, a 2.1% YoY decline. Profit Before Tax fell 87.1% YoY to ₹57.64 lakhs from ₹446.29 lakhs, with the PBT margin compressing to 0.35% from 2.63% in FY25. Net Profit After Tax (PAT) decreased 88.6% YoY to ₹35.28 lakhs. The sharp drop in profitability was driven by lower revenues and significantly higher purchase costs relative to sales. The board also noted the resignation of Company Secretary Rahul Joshi, effective 01 Jul'26.
Mono Pharmacare Limited has informed the Exchange regarding Resignation of Mr Rahul Joshi as Company Secretary & Compliance Officer of the company w.e.f. July 01, 2026.
Change in Management · 16 Jul 2026, 11:10 pm
Mono Pharmacare Company Secretary Resigns Citing Non-Payment of Salary Mr. Rahul Joshi has resigned from his position as Company Secretary and Compliance Officer of Mono Pharmacare Limited, effective 01 Jul'26. The company's filing on 16 Jul'26 states the reason for resignation is "pending salary dues and continued non-payment of salary." This is a significant governance flag, as the role is crucial for regulatory compliance. Mr. Joshi confirmed there were no other material reasons for his departure. The Board of Directors has accepted the resignation.
Mono Pharmacare Limited has informed the Exchange about Change in Company Secretary/Compliance Officer
Change in Management · 16 Jul 2026, 9:38 pm
Mono Pharmacare Company Secretary Resigns Citing Non-Payment of Salary Mr. Rahul Joshi has resigned as Company Secretary and Compliance Officer of Mono Pharmacare, effective 01 Jul'26. The resignation was explicitly attributed to pending salary dues and continued non-payment of salary. The company's board accepted the resignation on 16 Jul'26. Mr. Joshi confirmed there were no other material reasons for his departure, a detail which potentially highlights operational or financial stress within the company.
Mono Pharmacare Limited has submitted to the Exchange, the financial results for the year ended March 31, 2026.
Outcome · 16 Jul 2026, 9:30 pm
Mono Pharmacare FY26 Results: PAT Declines Amidst Lower Revenue Mono Pharmacare reported a standalone PAT of ₹35.30 lakhs for FY ended 31 Mar'26, an 88.6% YoY decline from ₹309.02 lakhs. Revenue from operations fell 11.8% YoY to ₹9,291.24 lakhs. On a consolidated basis, PAT for FY26 stood at ₹35.28 lakhs, down 88.7% YoY from ₹309.02 lakhs, while revenue decreased 1.6% YoY to ₹16,569.19 lakhs. The board also noted the resignation of Mr. Rahul Joshi as Company Secretary, effective 01 Jul'26, and appointed new internal and secretarial auditors.
Mono Pharmacare Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Acquisition/ Disposal of Shares · 14 Jul 2026, 7:45 pm
Mono Pharmacare Promoters Declare No Share Encumbrances for FY26 Mono Pharmacare Limited (NSE: MONOPHARMA) promoters have declared zero encumbrances on their shares for the financial year ended 31st Mar'26. This disclosure, dated 9th Jul'26, was made under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The declaration, submitted by Promoter Panilam Lakhatariya, confirms no shares held by the promoter group are pledged or otherwise encumbered, signaling stability in promoter holdings.
MONOPHARMA : 16-Jul-2026 : The Company has informed the Exchange that a Board meeting to be held on July 09, 2026 has been re-scheduled. Further, the Company has informed the Exchange that the meeting of the Board of Directors of the Company will be held on July 16, 2026, , To consider and approve the financial results for the period ended March 31, 2026 and other business matters
Financial Result · 10 Jul 2026, 12:01 am
Mono Pharmacare Board Meeting Rescheduled to 16 Jul'26 Mono Pharmacare Limited has rescheduled its Board Meeting from 09 Jul'26 to 16 Jul'26, citing unavoidable circumstances. The agenda includes the consideration and approval of financial results for the period ended 31 Mar'26. In accordance with insider trading regulations, the trading window will remain closed until the financial statement is declared and will reopen thereafter as per applicable rules. This notice is pursuant to SEBI (LODR) Regulations, 2015. The meeting will be held at the company's registered office.
Mono Pharmacare Limited has informed the Exchange regarding ''Board comments on fine levied by exchange'.
Others (Uncategorized) · 02 Jul 2026, 9:42 pm
Mono Pharmacare Fined by NSE for Regulatory Non-Compliance Mono Pharmacare was fined ₹96,760 by the National Stock Exchange (NSE) for non-compliance with Regulation 31 of SEBI's LODR Regulations. Following notices dated 14 May'26 and 01 Jun'26, the company acknowledged the inadvertent delay and confirmed immediate corrective actions were taken to ensure compliance. The Board has advised management to strengthen internal compliance monitoring mechanisms to prevent future lapses. The communication to the exchange was dated 02 Jul'26.
Mono Pharmacare Limited has informed the Exchange regarding ''.
Others (Uncategorized) · 02 Jul 2026, 9:39 pm
Mono Pharmacare Fined by NSE for Regulatory Non-Compliance Mono Pharmacare disclosed it was fined ₹20,060 by the NSE for non-compliance with SEBI's LODR Regulation 13(3) and Depository Participants Regulation 76. The notice was dated 20 May'26. Management stated the delay was inadvertent and has since taken corrective actions to ensure compliance. The Board has acknowledged the lapse and instructed management to strengthen internal compliance monitoring to prevent future occurrences. The company has paid the fine imposed by the exchange.
Revised voting result uploaded due to clerical error
Annual General Meeting · 02 Jul 2026, 6:13 pm
Mono Pharmacare EGM Resolutions Passed Unanimously Mono Pharmacare announced that all resolutions at its Extra-Ordinary General Meeting on 30th Jun'26 were passed with 100% of votes in favor. Key resolutions included the appointment of a statutory auditor to fill a casual vacancy and the appointment of Ms. Nirmala Ranawat as an Independent Director. Total voter turnout was 56.96% of outstanding shares, combining remote e-voting and poll results. No votes were cast against any of the resolutions, indicating unanimous shareholder approval for the proposed board and audit changes.
Mono Pharmacare Limited has submitted the Exchange a copy Srutinizers report of Extraordinary General Meeting held on Jun 30, 2026. Further, the company has informed the Exchange regarding voting results.
Annual General Meeting · 02 Jul 2026, 5:34 pm
Mono Pharmacare EGM Resolutions Passed With Unanimous Shareholder Approval At the Extra-Ordinary General Meeting on 30th Jun'26, shareholders of Mono Pharmacare passed all resolutions with 100% of votes in favour. Key approvals include the appointment of a new statutory auditor to fill a casual vacancy and the appointment of Ms. Nirmala Ranawat as an Independent Director. Overall voter turnout was 56.96% of the total share capital, with both promoter and public shareholders voting unanimously in favour of the proposed agenda items via e-voting and poll.